Diabetes RElated to Acute Pancreatitis and Its Mechanisms: Metabolic Outcomes Using Novel CGM Metrics

Summary

The DREAM-ON study will investigate whether continuous glucose monitoring (CGM) is useful to predict risk for developing diabetes mellitus (DM) and pre-diabetes mellitus (PDM), the need for insulin therapy among those who develop DM, and to determine whether CGM can provide insight into the pathophysiology and DM subtype among participants who have experienced an episode of acute pancreatitis (AP). Thus, the results of the DREAM-ON study could inform future clinical practice guidelines for the management AP as well as potentially extending the licensing authorization for CGM to include use in patients with pancreatogenic (Type 3c) DM.

Conditions

• Acute Pancreatitis

Interventions

DEVICE

Dexcom Continuous Glucose Monitor (CGM)

Dexcom Continuous Glucose Monitor which measures and records a participant's serum glucose level

Sponsors & Collaborators

• National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

  collaborator NIH

• Benaroya Research Institute

  collaborator OTHER

• Cedars-Sinai Medical Center

  collaborator OTHER

• University of Southern California

  collaborator OTHER

• Indiana University

  collaborator OTHER

• Johns Hopkins University

  collaborator OTHER

• Ohio State University

  collaborator OTHER

• Stanford University

  collaborator OTHER

• University of Florida

  collaborator OTHER

• AdventHealth

  collaborator OTHER

• University of Illinois at Chicago

  collaborator OTHER

• Northwestern University

  collaborator OTHER

• University of Minnesota

  collaborator OTHER

• University of Pittsburgh

  collaborator OTHER

• Milton S. Hershey Medical Center

  lead OTHER

Principal Investigators

• Vernon M Chinchilli, PhD · Penn State College of Medicine

• Richard E Pratley, MD · AdventHealth

Eligibility

Min Age

18 Years

Max Age

75 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2024-10-16

Primary Completion

2026-12-31

Completion

2027-03-31

FDA Device

Yes

Countries

• United States

Study Locations